Aims: This study aims to assess the side effects and mortality risks of different antidepressants. Methods: We utilized integrated databases, the National Health and Nutrition Examination Survey (NHANES) 2005-2018, to investigate the relationship between various antidepressants and health outcomes. Overall, 11 antidepressants were included in the main analysis, each used by at least 100 individuals with an average medication of over 40 months. Hazard ratios (HRs) and restricted mean survival time (RMST) were estimated to quantify differences in survival outcomes. Depression was assessed using the Patient Health Questionnaire-9. Results: A total of 5077 participants with depression were included. After adjustment, all antidepressants use had a trend toward increased long sleep duration risk (odds ratio [OR] range, 1.84-3.72; all p < 0.05) and reduced suicidal ideation risk (OR range, 0.25-0.47; all p < 0.05), except for mirtazapine. Users of bupropion, citalopram, duloxetine, sertraline, fluoxetine, and venlafaxine had higher obesity risk (OR range, 1.26-1.44; all p < 0.05). Only bupropion and escitalopram users were at lower risk for all-cause mortality, with an adjusted hazard ratio (aHR) of 0.66 (95% CI, 0.45 - 0.97; p = 0.036) for bupropion and 0.68 (95% CI, 0.47 - 0.93; p = 0.019) for escitalopram. Escitalopram users showed the most significant survival benefit (RMST difference, 30.1 [95% CI, 25.2-35.0] months; p < 0.001). Conclusions: Real-world evidence indicates that antidepressants have an extensive impact on overall health. Escitalopram is linked to reduced mortality risk and improved survival outcomes, suggesting its potential as a better treatment option for depression.